ArticleAIDS research and human retroviruses2015
Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
Article in AIDS research and human retroviruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Review
- Targeting Latent HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors.Viruses · 2025Article
- Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.Human vaccines & immunotherapeutics · 2021Review
- Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.The Journal of clinical investigation · 2020Article
- Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.Current opinion in HIV and AIDS · 2020Review
- Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.Antimicrobial agents and chemotherapy · 2019Review
- HIV Eradication Strategies: Implications for the Central Nervous System.Current HIV/AIDS reports · 2019Review
- Review
- Broadly neutralizing antibodies in HIV-1 treatment and prevention.Therapeutic advances in vaccines and immunotherapy · 2018Review
- Use of 'eradication' in HIV cure-related research: a public health debate.BMC public health · 2018Article
- Natural killer cells in HIV-1 infection and therapy.AIDS (London, England) · 2017Review
- PotentJournal of virology · 2017Article
- Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV.AIDS (London, England) · 2017Review
- Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.Current opinion in HIV and AIDS · 2017Review
- Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.Journal of virology · 2017Article
- Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Frontiers in immunology · 2017Review
- Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.Mucosal immunology · 2016Article
- Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play.Emerging microbes & infections · 2016Review
- International AIDS Society global scientific strategy: towards an HIV cure 2016.Nature medicine · 2016Article
- Engineering broadly neutralizing antibodies for HIV prevention and therapy.Advanced drug delivery reviews · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HIV field has seen an increased interest in novel cure strategies. In particular, new latency reversal agents are in development to reverse latency to flush the virus out of its hiding place. Combining these efforts with immunotherapeutic approaches may not only drive the virus out of latency, but allow for the rapid elimination of these infected cells in a "shock and kill" approach. Beyond cell-based approaches, growing interest lies in the potential use of functionally enhanced "killer" monoclonal therapeutics to purge the reservoir. Here we discuss prospects for a monoclonal therapeutic-based "shock and kill" strategy that may lead to the permanent elimination of replication-competent virus, making a functional cure a reality for all patients afflicted with HIV worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.